Skip to content
evident
Original paper
1994JAMAHospital Medicine/General Medicine

Saitz symptom-triggered alcohol withdrawal trial

Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial

RCTAlcohol withdrawal

On this page

Overview

On a VA detox unit, symptom-triggered chlordiazepoxide shortened treatment and reduced dose versus a fixed schedule, with similar withdrawal severity.

Clinical takeaway

Symptom-triggered dosing used less chlordiazepoxide and a shorter treatment course than fixed-schedule therapy, without a significant difference in withdrawal severity, seizures, or delirium tremens in this selected detox population.

Key result

Median treatment duration was 9 hours with symptom-triggered therapy vs 68 hours with fixed-schedule therapy (P<0.001). Patients received 100 mg vs 425 mg of chlordiazepoxide (P<0.001).

Practice impact

If a validated withdrawal score is available, symptom-triggered chlordiazepoxide can shorten treatment and lower benzodiazepine dose versus a standing schedule.

Evidence

Study design

Randomized, double-blind, controlled trial on an inpatient detoxification unit in a Veterans Affairs medical center.

Enrollment

101

Follow-up

Not listed

Geography

Not listed

Clinical question

Does symptom-triggered chlordiazepoxide reduce the duration and amount of medication used for alcohol withdrawal compared with a fixed schedule?

Population

  • One hundred one patients admitted for alcohol withdrawal who could give informed consent and had no history of seizures or of medication use that might alter the clinical course of withdrawal.

Intervention

Symptom-triggered therapy: chlordiazepoxide only in response to signs and symptoms of alcohol withdrawal, with as-needed doses guided by a validated withdrawal-severity measure.

Comparator

Fixed-schedule therapy: a standard course of chlordiazepoxide four times daily, with additional medication as needed.

Primary outcome

Duration of medication treatment and total chlordiazepoxide administered.

Symptom-triggered therapy shortened median treatment duration (9 vs 68 hours) and reduced chlordiazepoxide use (100 mg vs 425 mg) compared with fixed-schedule therapy, without significant differences in withdrawal severity, seizures, or delirium tremens.

p<0.001

Key results

  • Median duration of treatment was 9 hours in the symptom-triggered group vs 68 hours in the fixed-schedule group (P<0.001).
  • The symptom-triggered group received 100 mg of chlordiazepoxide vs 425 mg in the fixed-schedule group (P<0.001).
  • There were no significant differences in the severity of withdrawal during treatment or in the incidence of seizures or delirium tremens.

Harms

  • There were no significant differences in the incidence of seizures or delirium tremens.

Clinical Use

Practice impact

  • On a monitored detox unit, symptom-triggered chlordiazepoxide can individualize treatment and cut both duration and benzodiazepine dose versus a standing four-times-daily schedule.
  • The trial found no significant difference in seizures or delirium tremens; that is not the same as proving equal safety on every ward.

Applicability

  • Most applicable to patients admitted to a Veterans Affairs inpatient detoxification unit for alcohol withdrawal who can consent and who do not have a seizure history or medications that might change the withdrawal course.

Limitations

  • Patients with a history of seizures were excluded.
  • The setting was a Veterans Affairs detoxification unit, not a general medical ward.
  • The abstract does not report a follow-up interval beyond the treatment period.
  • The 100 mg and 425 mg chlordiazepoxide totals are not labeled as medians in the abstract; only treatment duration is specified as a median.

Common misinterpretations

  • This is not a trial of untreated withdrawal. Both arms used chlordiazepoxide; the question was when to give it.
  • Results should not be applied to patients with prior withdrawal seizures; they were excluded.

Citation

Saitz R, Mayo-Smith MF, Roberts MS, Redmond HA, Bernard DR, Calkins DR. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA. 1994;272(7):519-523.

Symptom-triggered therapy individualizes treatment, decreases both treatment duration and the amount of benzodiazepine used, and is as efficacious as standard fixed-schedule therapy for alcohol withdrawal.
DOI
Not listed